COMP <GO>
ACRV vs MNOV // ALTMAN Z-SCORE & DEBT/EQUITY
Acrivon Therapeutics Inc. (NASDAQ) VS. Medicinova Inc (NASDAQ) • 15-METRIC TALLY: ACRV 0
— MNOV 2
■ METRIC PARITY
LAST: $1.67 (+3.73%) • MKT CAP: $69.0M
balance-sheet
—
LAST: $1.42 (-1.39%) • MKT CAP: $70.9M
balance-sheet
0.20
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACRV VS. MNOV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACRV | MNOV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -14.24% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.2 | 41.6 | -5.40 | MNOV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 5.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $69.0M | $70.9M | -$1.9M | MNOV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACRV REV | MNOV REV | ACRV GROSS % | MNOV GROSS % | ACRV FCF | MNOV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $235.5M | $409.7K | — | — | -$65.3M | -$9.8M |
| FY 2024 | $249.8M | $35.5M | — | — | -$68.4M | -$10.6M |
| FY 2023 | $187.9M | $1.0M | — | — | -$42.6M | -$7.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACRV // BETA —
MNOV // BETA —